Clinical Trials Browser

Phase 2 × Withdrawn × Hematologic Diseases × Clear all

NCT04258683 2023-08-29

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Phase 2 Withdrawn

Plasma cell

Cardiovascular Diseases, Hematologic Diseases, Immune System Diseases, Multiple Myeloma, Neoplasms

NCT04282174 2022-09-27

2019-KOE-001

Phase 2 Withdrawn

LymphoidMyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04127721 2020-10-29

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Phase 2 Withdrawn

Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

NCT00594555 2008-10-31

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

Phase 2 Withdrawn

20 enrolled

MyeloidOther hematologic neoplasm

Blast Crisis, Hematologic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute